4d7g - Revision history

OCA at 07:50, 14 September 2022

OCA — Wed, 14 Sep 2022 07:50:54 GMT

←Older revision		Revision as of 07:50, 14 September 2022
Line 3:		Line 3:
	<StructureSection load='4d7g' size='340' side='right'caption='[[4d7g]], [[Resolution\|resolution]] 2.33Å' scene=''>		<StructureSection load='4d7g' size='340' side='right'caption='[[4d7g]], [[Resolution\|resolution]] 2.33Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4d7g]] is a 1 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4D7G OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4D7G FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4d7g]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4D7G OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4D7G FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=E6U:N-[(1S)-1-BENZYL-2-(3-GUANIDINOPROPYLAMINO)-2-OXO-ETHYL]-4-HYDROXY-2-OXO-1H-QUINOLINE-6-CARBOXAMIDE'>E6U</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=TRS:2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL'>TRS</scene~~></td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=E6U:N-[(1S)-1-BENZYL-2-(3-GUANIDINOPROPYLAMINO)-2-OXO-ETHYL]-4-HYDROXY-2-OXO-1H-QUINOLINE-6-CARBOXAMIDE'>E6U</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=TRS:2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL'>TRS</scene></td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4d76\|4d76]], [[4d7f\|4d7f]]</td></tr>~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4d7g FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4d7g OCA], [https://pdbe.org/4d7g PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4d7g RCSB], [https://www.ebi.ac.uk/pdbsum/4d7g PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4d7g ProSAT]</span></td></tr>
-	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Coagulation_factor_XIa Coagulation factor XIa], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.27 3.4.21.27] </span></td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4d7g FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4d7g OCA], [~~http~~://pdbe.org/4d7g PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4d7g RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4d7g PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4d7g ProSAT]</span></td></tr>	+
	</table>		</table>
	== Disease ==		== Disease ==
-	[[~~http~~://www.uniprot.org/uniprot/FA11_HUMAN FA11_HUMAN]] Defects in F11 are the cause of factor XI deficiency (FA11D) [MIM:[~~http~~://omim.org/entry/612416 612416]]; also known as plasma thromboplastin antecedent deficiency or Rosenthal syndrome. It is a hemorrhagic disease characterized by reduced levels and activity of factor XI resulting in moderate bleeding symptoms, usually occurring after trauma or surgery. Patients usually do not present spontaneous bleeding but women can present with menorrhagia. Hemorrhages are usually moderate.<ref>PMID:2813350</ref> <ref>PMID:1547342</ref> <ref>PMID:7888672</ref> <ref>PMID:7669672</ref> <ref>PMID:9401068</ref> <ref>PMID:9787168</ref> <ref>PMID:10027710</ref> <ref>PMID:10606881</ref> <ref>PMID:11895778</ref> <ref>PMID:15026311</ref> <ref>PMID:15180874</ref> <ref>PMID:15953011</ref> <ref>PMID:16607084</ref> <ref>PMID:18005151</ref> <ref>PMID:21668437</ref> <ref>PMID:21457405</ref> <ref>PMID:22016685</ref> <ref>PMID:22322133</ref> <ref>PMID:21999818</ref> <ref>PMID:22159456</ref>	+	[[https://www.uniprot.org/uniprot/FA11_HUMAN FA11_HUMAN]] Defects in F11 are the cause of factor XI deficiency (FA11D) [MIM:[https://omim.org/entry/612416 612416]]; also known as plasma thromboplastin antecedent deficiency or Rosenthal syndrome. It is a hemorrhagic disease characterized by reduced levels and activity of factor XI resulting in moderate bleeding symptoms, usually occurring after trauma or surgery. Patients usually do not present spontaneous bleeding but women can present with menorrhagia. Hemorrhages are usually moderate.<ref>PMID:2813350</ref> <ref>PMID:1547342</ref> <ref>PMID:7888672</ref> <ref>PMID:7669672</ref> <ref>PMID:9401068</ref> <ref>PMID:9787168</ref> <ref>PMID:10027710</ref> <ref>PMID:10606881</ref> <ref>PMID:11895778</ref> <ref>PMID:15026311</ref> <ref>PMID:15180874</ref> <ref>PMID:15953011</ref> <ref>PMID:16607084</ref> <ref>PMID:18005151</ref> <ref>PMID:21668437</ref> <ref>PMID:21457405</ref> <ref>PMID:22016685</ref> <ref>PMID:22322133</ref> <ref>PMID:21999818</ref> <ref>PMID:22159456</ref>
	== Function ==		== Function ==
-	[[~~http~~://www.uniprot.org/uniprot/FA11_HUMAN FA11_HUMAN]] Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX.	+	[[https://www.uniprot.org/uniprot/FA11_HUMAN FA11_HUMAN]] Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX.

	==See Also==		==See Also==
Line 20:		Line 18:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Coagulation factor XIa]]~~	+	[[Category: Homo sapiens]]
-	~~[[Category: Human~~]]	+
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Akerud, T]]	+	[[Category: Akerud T]]
-	[[Category: Borjesson, U]]	+	[[Category: Borjesson U]]
-	[[Category: Jacso, T]]	+	[[Category: Jacso T]]
-	[[Category: Norberg, M]]	+	[[Category: Norberg M]]
-	[[Category: Olsson, T]]	+	[[Category: Olsson T]]
-	[[Category: Oster, L]]	+	[[Category: Oster L]]
-	[[Category: Redzick, A]]	+	[[Category: Redzick A]]
-	[[Category: Sandmark, J]]	+	[[Category: Sandmark J]]
-	[[Category: Ullah, V]]	+	[[Category: Ullah V]]
-	~~[[Category: Hydrolase]]~~	+
-	~~[[Category: Serine protease~~]]	+

OCA at 08:07, 27 March 2019

OCA — Wed, 27 Mar 2019 08:07:08 GMT

←Older revision		Revision as of 08:07, 27 March 2019
Line 1:		Line 1:
		+
	==Human FXIa in complex with small molecule inhibitors.==		==Human FXIa in complex with small molecule inhibitors.==
-	<StructureSection load='4d7g' size='340' side='right' caption='[[4d7g]], [[Resolution\|resolution]] 2.33Å' scene=''>	+	<StructureSection load='4d7g' size='340' side='right'caption='[[4d7g]], [[Resolution\|resolution]] 2.33Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4d7g]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4D7G OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4D7G FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4d7g]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4D7G OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4D7G FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=E6U:N-[(1S)-1-BENZYL-2-(3-GUANIDINOPROPYLAMINO)-2-OXO-ETHYL]-4-HYDROXY-2-OXO-1H-QUINOLINE-6-CARBOXAMIDE'>E6U</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=TRS:2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL'>TRS</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=E6U:N-[(1S)-1-BENZYL-2-(3-GUANIDINOPROPYLAMINO)-2-OXO-ETHYL]-4-HYDROXY-2-OXO-1H-QUINOLINE-6-CARBOXAMIDE'>E6U</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=TRS:2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL'>TRS</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4d76\|4d76]], [[4d7f\|4d7f]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4d76\|4d76]], [[4d7f\|4d7f]]</td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Coagulation_factor_XIa Coagulation factor XIa], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.27 3.4.21.27] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Coagulation_factor_XIa Coagulation factor XIa], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.27 3.4.21.27] </span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4d7g FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4d7g OCA], [http://pdbe.org/4d7g PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4d7g RCSB], [http://www.ebi.ac.uk/pdbsum/4d7g PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4d7g FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4d7g OCA], [http://pdbe.org/4d7g PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4d7g RCSB], [http://www.ebi.ac.uk/pdbsum/4d7g PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4d7g ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 12:		Line 13:
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/FA11_HUMAN FA11_HUMAN]] Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX.		[[http://www.uniprot.org/uniprot/FA11_HUMAN FA11_HUMAN]] Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX.
		+
		+	==See Also==
		+	*[[Factor XIa\|Factor XIa]]
	== References ==		== References ==
	<references/>		<references/>
Line 17:		Line 21:
	</StructureSection>		</StructureSection>
	[[Category: Coagulation factor XIa]]		[[Category: Coagulation factor XIa]]
		+	[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Akerud, T]]		[[Category: Akerud, T]]
	[[Category: Borjesson, U]]		[[Category: Borjesson, U]]

OCA at 17:09, 20 January 2016

OCA — Wed, 20 Jan 2016 17:09:41 GMT

←Older revision		Revision as of 17:09, 20 January 2016
Line 1:		Line 1:
-	'''~~Unreleased structure~~'''	+	==Human FXIa in complex with small molecule inhibitors.==
-		+	<StructureSection load='4d7g' size='340' side='right' caption='[[4d7g]], [[Resolution\|resolution]] 2.33Å' scene=''>
-	~~The entry~~ 4d7g is ~~ON HOLD until Paper Publication~~	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[4d7g]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4D7G OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4D7G FirstGlance]. <br>
-	~~Authors~~: ~~Sandmark, J~~.~~, Oster, L~~.~~, Jacso, T~~.~~, Ullah, V~~.~~, Redzick, A~~.~~, Borjesson, U~~.~~, Olsson, T~~., ~~Norberg~~, M., ~~Akerud~~, T.	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=E6U:N-[(1S)-1-BENZYL-2-(3-GUANIDINOPROPYLAMINO)-2-OXO-ETHYL]-4-HYDROXY-2-OXO-1H-QUINOLINE-6-CARBOXAMIDE'>E6U</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=TRS:2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL'>TRS</scene></td></tr>
-		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4d76\|4d76]], [[4d7f\|4d7f]]</td></tr>
-	~~Description~~: ~~Human FXIa in complex~~ with ~~small molecule inhibitors~~.	+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Coagulation_factor_XIa Coagulation factor XIa], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.27 3.4.21.27] </span></td></tr>
-	[[~~Category~~: ~~Unreleased Structures~~]]	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4d7g FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4d7g OCA], [http://pdbe.org/4d7g PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4d7g RCSB], [http://www.ebi.ac.uk/pdbsum/4d7g PDBsum]</span></td></tr>
-	[[~~Category~~: ~~Norberg~~, M]]	+	</table>
-	[[~~Category~~: ~~Redzick, A~~]]	+	== Disease ==
-	[[~~Category~~: ~~Oster, L~~]]	+	[[http://www.uniprot.org/uniprot/FA11_HUMAN FA11_HUMAN]] Defects in F11 are the cause of factor XI deficiency (FA11D) [MIM:[http://omim.org/entry/612416 612416]]; also known as plasma thromboplastin antecedent deficiency or Rosenthal syndrome. It is a hemorrhagic disease characterized by reduced levels and activity of factor XI resulting in moderate bleeding symptoms, usually occurring after trauma or surgery. Patients usually do not present spontaneous bleeding but women can present with menorrhagia. Hemorrhages are usually moderate.<ref>PMID:2813350</ref> <ref>PMID:1547342</ref> <ref>PMID:7888672</ref> <ref>PMID:7669672</ref> <ref>PMID:9401068</ref> <ref>PMID:9787168</ref> <ref>PMID:10027710</ref> <ref>PMID:10606881</ref> <ref>PMID:11895778</ref> <ref>PMID:15026311</ref> <ref>PMID:15180874</ref> <ref>PMID:15953011</ref> <ref>PMID:16607084</ref> <ref>PMID:18005151</ref> <ref>PMID:21668437</ref> <ref>PMID:21457405</ref> <ref>PMID:22016685</ref> <ref>PMID:22322133</ref> <ref>PMID:21999818</ref> <ref>PMID:22159456</ref>
-	[[~~Category~~: ~~Ullah, V~~]]	+	== Function ==
-	[[Category: ~~Olsson, T~~]]	+	[[http://www.uniprot.org/uniprot/FA11_HUMAN FA11_HUMAN]] Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX.
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Coagulation factor XIa]]
	[[Category: Akerud, T]]		[[Category: Akerud, T]]
	[[Category: Borjesson, U]]		[[Category: Borjesson, U]]
-	[[Category: Sandmark, J]]
	[[Category: Jacso, T]]		[[Category: Jacso, T]]
		+	[[Category: Norberg, M]]
		+	[[Category: Olsson, T]]
		+	[[Category: Oster, L]]
		+	[[Category: Redzick, A]]
		+	[[Category: Sandmark, J]]
		+	[[Category: Ullah, V]]
		+	[[Category: Hydrolase]]
		+	[[Category: Serine protease]]

OCA at 08:25, 15 July 2015

OCA — Wed, 15 Jul 2015 08:25:49 GMT

←Older revision		Revision as of 08:25, 15 July 2015
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 4d7g is ON HOLD	+	The entry 4d7g is ON HOLD until Paper Publication

	Authors: Sandmark, J., Oster, L., Jacso, T., Ullah, V., Redzick, A., Borjesson, U., Olsson, T., Norberg, M., Akerud, T.		Authors: Sandmark, J., Oster, L., Jacso, T., Ullah, V., Redzick, A., Borjesson, U., Olsson, T., Norberg, M., Akerud, T.

OCA at 13:57, 24 December 2014

OCA — Wed, 24 Dec 2014 13:57:06 GMT

←Older revision		Revision as of 13:57, 24 December 2014
Line 6:		Line 6:

	Description: Human FXIa in complex with small molecule inhibitors.		Description: Human FXIa in complex with small molecule inhibitors.
		+	[[Category: Unreleased Structures]]
		+	[[Category: Norberg, M]]
		+	[[Category: Redzick, A]]
		+	[[Category: Oster, L]]
		+	[[Category: Ullah, V]]
		+	[[Category: Olsson, T]]
		+	[[Category: Akerud, T]]
		+	[[Category: Borjesson, U]]
		+	[[Category: Sandmark, J]]
		+	[[Category: Jacso, T]]

OCA: Protected "4d7g" [edit=sysop:move=sysop]

OCA — Wed, 03 Dec 2014 08:02:05 GMT

Protected "4d7g" [edit=sysop:move=sysop]

←Older revision

Revision as of 08:02, 3 December 2014

OCA: New page: '''Unreleased structure''' The entry 4d7g is ON HOLD Authors: Sandmark, J., Oster, L., Jacso, T., Ullah, V., Redzick, A., Borjesson, U., Olsson, T., Norberg, M., Akerud, T. Description...

OCA — Wed, 03 Dec 2014 08:02:04 GMT

New page: '''Unreleased structure''' The entry 4d7g is ON HOLD Authors: Sandmark, J., Oster, L., Jacso, T., Ullah, V., Redzick, A., Borjesson, U., Olsson, T., Norberg, M., Akerud, T. Description...

New page

'''Unreleased structure'''

The entry 4d7g is ON HOLD

Authors: Sandmark, J., Oster, L., Jacso, T., Ullah, V., Redzick, A., Borjesson, U., Olsson, T., Norberg, M., Akerud, T.

Description: Human FXIa in complex with small molecule inhibitors.